End-of-day quote
Other stock markets
|
||
- | - |
05-07 | AstraZeneca target raised; Antofagasta lowered | AN |
05-01 | HSS Hire Group CFO to Retire in September | MT |
Sales 2023 | 349M 445M 0 608M | Sales 2024 * | 347M 443M 0 605M | Capitalization | 70.5M 89.91M 0 123M |
---|---|---|---|---|---|
Net income 2023 | 4M 5.1M - 6.97M | Net income 2024 * | 6M 7.65M - 10.45M | EV / Sales 2023 | 0.24 x |
Net Debt 2023 * | 56.8M 72.44M 0 98.91M | Net Debt 2024 * | 95.22M 121M 0 166M | EV / Sales 2024 * | 0.48 x |
P/E ratio 2023 |
20.2
x | P/E ratio 2024 * |
11.4
x | Employees | - |
Yield 2023 * |
5.6% | Yield 2024 * |
5.77% | Free-Float | 24.68% |
Managers | Title | Age | Since |
---|---|---|---|
Stephen Ashmore
CEO | Chief Executive Officer | 60 | 17-05-31 |
Paul Quested
DFI | Director of Finance/CFO | 54 | 16-04-30 |
Daniel Joll
BRD | Director/Board Member | - | 15-05-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Director/Board Member | 67 | 15-01-08 | |
Director/Board Member | 71 | 15-01-08 | |
Alan Peterson
CHM | Chairman | 77 | 12-11-30 |
1st Jan change | Capi. | |
---|---|---|
+15.93% | 44.85B | |
+5.64% | 31.85B | |
+23.52% | 17.93B | |
-12.45% | 7.47B | |
+14.12% | 5.41B | |
-5.43% | 4.19B | |
-6.43% | 3.59B | |
-7.84% | 2.72B | |
+17.29% | 2.15B |